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Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) has become a leading cause of chronic liver disease worldwide. We aimed
to study this condition and liver fibrosis in bariatric patients at baseline using ultrasound, NAFLD fibrosis score (NFS), and fibrosis
index-4 (FIB-4).
Methods: Adult patients with morbid obesity without other possible causes of liver pathology were evaluated. Liver biopsy was
performed in a subset of patients. Diagnostic accuracy of tests was assessed using area under the receiver operating-characteristic
curve (AUROC).
Results: Overall, 1944 patients with mean age of 38.3± 10.8 years and body mass index of 44.6± 6.4 kg/m2 comprised the study
population. Liver Biopsy showed features of NAFLD in 70%; 60.3% had nonalcoholic fatty liver and 9.6% steatohepatitis. Older age and
higher transaminase levels were associated with higher NAFLD activity score. Fibrosis was present in 23.3% with the majority having
F1. Ultrasound detected steatosis in 76.8%, with two-thirds having grade I to II fatty liver. Metabolic syndrome, hemoglobin A1c,
age, and alanine transaminase were the strongest risk factors for fatty liver. Ultrasound showed an AUROC of 0.75 (95% confidence
interval 0.63-0.86) for NAFLD with a sensitivity and specificity of 72.5% and 68.2%, respectively (cutoff of grade II). For diagnosis of
fibrosis, FIB-4 had an AUROC of 0.72 (0.58-0.86) with 93.3% sensitivity and 43.1% specificity (cutoff of 0.50). NFS failed to show a
significant AUROC curve for diagnosing fibrosis.
Conclusions: Our findings confirmed a high prevalence of NAFLD in morbidly obese patients. Despite this high prevalence, fibrosis
was uncommon and low-grade. This study questions the use of current cutoffs for NFS and FIB-4 in all patients.
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1. Background
Non-alcoholic fatty liver disease (NAFLD) has become
the most common cause of liver dysfunction worldwide
and is highly prevalent in obese and morbidly obese pa-
tients (1, 2). It manifests as the presence of hepatic steato-
sis in the absence of alcohol-induced liver damage or other
causes of liver pathology. It is increasingly associated with
diabetes mellitus (DM), hyperlipidemia, and metabolic
syndrome (MetS) (3). Its underlying mechanism at the
cellular level centers on insulin resistance and an inter-
play of oxidative stress, lipid peroxidation, cytokines, and
adipokines (4). Ensuing deposition of fat leads to liver
steatosis and can progress to more severe liver damage in
the form of non-alcoholic steatohepatitis (NASH), fibrosis,
cirrhosis, and even carcinoma (5). In fact, untreated NAFLD
can result in advanced fibrosis in a few years, which per se
could significantly increase the mortality risk from coro-
nary heart disease, malignancy, and liver-related problems
(6, 7).
Reports on the prevalence of NAFLD have demon-
strated that this condition could be present in up to 67% of
overweight and 94% of obese patients, and the advanced
form of the disease, NASH, was reported in up to 77.5% in
a Japanese cohort (8). The prevalence is especially high in
patients with morbid obesity because of the accompanied
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MetS and insulin resistance (9). In a cross-sectional study
in the region of the current study, NAFLD was reported to
be present in 43.8% of the general population, increasing
to up to 70% in patients with MetS (10). However, regional
data regarding its prevalence and associated risk factors in
people with morbid obesity, as well as the risk of advanced
fibrosis is scarce.
Non-invasive diagnosis of NAFLD and liver fibrosis has
been the center of attention in recent years and various
tools have been suggested to replace liver biopsy (LB) (11).
Although liver ultrasound (US) lacks the desired diagnos-
tic accuracy in this regard, it has remained a convenient
and accessible method of initial liver evaluation (12). Nev-
ertheless, it is especially incapable of diagnosing fibrosis
and can only detect advanced stages when signs of cirrho-
sis have emerged. As a result, a number of simple tools
have recently been validated to predict the risk of liver fi-
brosis. Among these, NAFLD fibrosis score (NFS) (13) and
fibrosis-4 index (FIB-4) (14) have shown the best diagnos-
tic performance for advanced fibrosis and may be used to
complement the findings of liver chemistries and US (15).
These risk prediction algorithms are based solely on sim-
ple blood tests, age, and body mass index (BMI). Neverthe-
less, while LB has remained the gold standard for the di-
agnosis of NAFLD and assessment of fibrosis despite hav-
ing its own risks and shortcomings (16), these noninvasive
tools need to be thoroughly studied in various settings be-
fore they can be incorporated into everyday practice.
Given the epidemiologic impact of genetic and eth-
nic variations on NAFLD prevalence (17) and to investigate
the diagnostic utility of the aforementioned noninvasive
tools, we aimed to evaluate NAFLD and liver fibrosis in
a prospectively-maintained database of bariatric patients
and study the associated risks and predictive factors.
2. Methods
2.1. Study Population and Design
This study was a baseline evaluation of the Tehran Obe-
sity Treatment Study (TOTS), which is an ongoing prospec-
tive bariatric cohort commenced in March 2013. A detailed
study protocol for TOTS is available elsewhere (18). Briefly,
after providing written informed consent, morbidly obese
patients undergo laparoscopic Roux-en-Y gastric bypass,
mini-gastric bypass, or sleeve gastrectomy by a single sur-
gical team and are followed postoperatively. A wide range
of variables including anthropometric and laboratory in-
dices are collected at baseline, intraoperatively, and post-
operatively.
Of the 2007 patients in the database after exclusion of
those with a BMI < 35 kg/m2 (n = 11), history of heavy alcohol
consumption (defined as average daily pure alcohol con-
sumption of 20 g for females and 30 g for males, or history
of past excessive drinking for a period of two years at any
time during the past 20 years) (n = 33), seropositivity for
hepatitis viruses, or hepatotoxic medication use (n = 5), or
age younger than 18 years (n = 14), 1944 participants were
selected for the current study.
Preoperative laboratory and anthropometric indices
included, but were not limited to, liver function tests (as-
partate transaminase (AST), alanine transaminase (ALT),
alkaline phosphatase (ALP), and albumin), lipid profile
(high-density lipoprotein cholesterol (HDL), low-density
lipoprotein cholesterol (LDL), total cholesterol level, and
serum triglyceride level (TG)), complete blood count, fast-
ing plasma glucose (FPG), serum insulin, and glycosylated
hemoglobin (HbA1c) level. US was performed in the imme-
diate preoperative period in all patients by a skilled radiol-
ogist to assess liver span and grade fatty liver from 0 to 3,
based on the severity of echogenicity.
2.2. Liver Biopsy (LB)
A subset of patients (n = 73) agreed and consented to
undergo LB at the time of surgery. Biopsies were taken
from the left liver lobe, percutaneously with a 16-gauge
Tru-Cut needle (BARD-Max core, Covington, GA, USA), and
right liver lobe by wedge biopsy under laparoscopic guid-
ance. This approach ensured that enough tissue would
be obtained for evaluation and provided specimens for fu-
ture molecular and immunohistochemical studies (18). An
experienced liver pathologist blinded to baseline charac-
teristics and laboratory data of patients assessed all biop-
sies using hematoxylin and eosin, Masson’s trichrome, and
iron staining. Diagnosis of NAFLD or NASH was made af-
ter thorough histologic evaluation of samples. Specimens
were evaluated according to NASH-clinical research net-
work’s (NASH-CRN) NAFLD activity score (NAS) criteria (19),
which scores three key histologic features of steatosis from
0 to 3, lobular inflammation from 0 to 3, and hepatocyte
ballooning from 0 to 2, producing a total score range from
zero to eight. Histologic features of fibrosis were also as-
sessed, from F0 (no fibrosis) to F4 (cirrhosis), based on the
criteria proposed by Kleiner et al. (19). Other tissue features
were also assessed to provide a complete pathology report.
2.3. Definitions
MetS was present if at least three of five criteria accord-
ing to the Joint Interim Statement (JIS) definition were met
(20). High transaminase level was defined as AST levels
≥ 33 U/L or 29 U/L and ALT levels ≥ 43 U/L or 30 U/L in
males and females, respectively. Normal liver was defined
by either having a normal LB (NAS of 0) or normal liver US
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(grade 0 fatty liver) in whom LB was not performed; oth-
erwise, patients were categorized as having fatty liver ac-
cording to LB results (NAS of 1 to 4 as non-alcoholic fatty
liver (NAFL), and NAS of 5 to 8 as NASH) or liver US (grade
I-III corresponding to mild to severe steatosis). For fibrosis,
F2 to F4 was defined as significant fibrosis (SF).
Homeostatic model assessment of insulin resistance
index (HOMA-IR) was calculated according to the standard
equation and a value above 2.50 mol × µU/L was consid-
ered as insulin resistant (IR) (21). NFS was calculated in
all NAFLD patients using the formula: -1.675 + 0.037× age
(year) + 0.094× BMI (kg/m2) + 1.13× impaired fasting glu-
cose/DM (present = 1, absent = 0) + 0.99 × AST/ALT ratio -
0.013× platelet count (109/L) - 0.66× albumin (g/dL); sub-
jects were categorized as having low, intermediate, or high
probability of advanced fibrosis, if they scored less than
-1.5, between -1.5 and 0.676, or higher than 0.676, respec-
tively. Moreover, the FIB-4 index was calculated according
to the formula: (age (year)× AST (U/L)) / (platelet (109/L)×
ALT (U/L)1/2 ), and categorized using cutoffs of 1.45 and 3.25.
2.4. Statistical Analysis
Statistical analyses were performed using SPSS version
21.0 software (SPSS Inc., Chicago, IL, USA). Descriptive statis-
tics were reported as mean ± standard deviation (SD) for
continuous variables and number (%) for categorical vari-
ables. Variables without a normal distribution were re-
ported as median [25 - 75 interquartile range (IQR)]. Stu-
dent t-test and analysis of variance (ANOVA) were used
to compare normally distributed continuous variables,
and Chi-squared test was used for categorical variables.
Mann-Whitney and Kruskal-Wallis tests were used for non-
normally distributed variables. Chi-squared and Fisher’s
exact tests were used to look for associations between dif-
ferent variables. The relationship between the presence
of NAFLD as the dependent variable and possible indepen-
dent predictive variables including age, gender, weight,
height, waist circumference (WC), BMI, DM, hypertension
(HTN), MetS, ALT, AST, ALP, albumin, HDL, LDL, total choles-
terol, TG, FPG, insulin, IR, HbA1c, and HOMA-IR was as-
sessed using binary logistic regression model with the en-
ter method. Those variables with a P value of < 0.2 in the
univariate model were selected for multivariate analysis
with the backward selection method. Odds ratio (OR) and
95% confidence intervals (95% CI) were calculated and re-
ported. P < 0.05 was considered statistically significant for
all comparisons.
Moreover, the association between LB and US for assess-
ing NAFLD was assessed; they were compared as three-level
variables (0, grade I to II, and grade III for US versus normal,
NAFL, and NASH for LB). Similarly, associations between
NFS or FIB-4 and fibrosis (normal liver versus F1-F4) were
calculated. Moreover, we calculated the area under the re-
ceiver operating characteristic curves (AUROC) of the diag-
nostic tests, as well as their optimized cutoffs for these di-
agnostic tests based on AUROC. Sensitivity, specificity, pos-
itive predictive value (PPV), and negative predictive value
(NPV) were calculated and reported for US, NFS, and FIB-4.
Any possible agreements between NFS and FIB-4 was fur-
ther assessed using the kappa statistic.
2.5. Ethical Considerations
Written informed consent was obtained from all par-
ticipants before the study, including a separate consent
for those undergoing LB. All procedures were performed
in accordance with the Helsinki Declaration and its later
amendments. The Human Research Review Committee of
the Endocrine Research Center, Shahid Beheshti Univer-
sity of Medical Sciences, approved this study (No.2ECRIES
93/03/13).
3. Results
Study participants included 1944 patients with mean
age of 38.3± 10.8 years, mean BMI of 44.6± 6.4 kg/m2, and
79% being female. MetS was present in 63.0%, HTN in 27.4%,
and DM in 22.6% of patients, and 75.9% were IR. Median AST
and ALT levels were 20 [16 - 26] U/L and 23 [17 - 34] U/L, re-
spectively, and 25.5% of patients had high ALT and 15.7% had
high AST levels (Table 1).
3.1. Liver Ultrasound
Liver steatosis was present in 76.8% of the patients;
482 (32.3%) had grade I, 664 (44.5%) had grade II, and 347
(23.2%) had grade III fatty liver (Table 2). Significant dif-
ferences were observed regarding most variables between
these groups, with more unfavorable values in higher fatty
liver grades. Total cholesterol, LDL, ALP, platelet count, and
serum albumin were comparable across groups. Patients
with grade-I fatty liver were older and had higher weight,
height, WC, HbA1c, and ALT levels than those with normal
liver. Those with grade II or III fatty liver had higher val-
ues than those with normal or grade I fatty liver for all vari-
ables. IR, MetS, and DM were also significantly more preva-
lent in those with grade III fatty liver, reaching 85.6%, 73.4%,
and 34%, respectively.
Logistic regression analysis revealed that DM (OR 2.46,
95% CI 1.75 to 3.44), MetS (OR 2.24, 95% CI 1.78 to 2.83), and
HTN (OR 1.78, 95%CI 1.36 to 2.34) increased the odds of hav-
ing fatty liver. Other factors associated with the presence
of fatty liver included age, weight, BMI, WC, FPG, ,HbA1c,
IR, HOMA-IR, high AST, high ALT, diastolic blood pressure,
and TG. On multivariate analysis, only Mets (OR 1.70, 95%CI
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Table 1. Demographic, Anthropometric, and Laboratory Measurements of All Study Participants As Well As Those Undergoing Liver Biopsy (N = 73)a
Variable Total (N = 1944) Underwent Biopsy (N = 73)
Age, y 38.3± 10.8 40.1± 10.9
Sex, female, % 79 72
Weight, kg 120.7± 21.9 125.7± 19.9
Height, cm 163.8± 9.1 165.5± 8.9
BMI, kg/m2 44.6± 6.4 45.9± 5.6
Waist circumference, cm 124.2± 14.5 127.2± 13.1
Systolic blood pressure, mmHg 122.8± 12.6 124.1± 10.6
Diastolic blood pressure, mmHg 78.0± 8.8 77.1± 7.5
Hypertension 533 (27.4) 22 (30.1)
Fasting plasma glucose, mg/dL 98 [90 - 112] 100 [92 - 116]
Insulin, mIU/L 17.4 [11 - 25] 18.9 [12 - 25.2]
Hemoglobin A1c, % 5.5 [5.1 - 6.1] 5.5 [5.1 - 6.0]
HOMA-IR 4.35 [2.66 - 6.78] 5.02 [3.28 - 6.61]
Insulin resistant 1100 (75.9) 45 (81.8)
Diabetes mellitus, % 22.6 24.3
Metabolic syndrome, % 63.0 68.6
Triglyceride, mg/dL 142 [104 - 194] 156 [119 - 200]
High-density lipoprotein, mg/dL 47.7± 11.6 46.9± 10.5
Low-density lipoprotein, mg/dL 111.5± 33.2 107.4± 34.8
Alkaline phosphatase, IU/L 188.4± 86.1 187.9± 49.1
AST, U/L 20 [16 - 26] 21 [16 - 27]
High AST 306 (15.7) 13 (17.8)
ALT, U/L 23 [17 - 34] 24 [18 - 34]
High ALT 496 (25.5) 20 (27.4)
Total cholesterol, mg/dL 191.8± 42.2 187.0± 43.6
Serum albumin, g/dL 4.3± 0.7 4.4± 0.3
Platelet count, 103 /microL 281.6± 66.3 268.3± 64.5
Liver span, cm 15.8± 2.2 16.7± 2.4
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; HOMA-IR, homeostatic model assessment of insulin resistance.
aValues are presented as mean± SD for normally distributed variables, median [IQR] for not normally distributed variables, or No. (%) for categorical variables.
1.15 to 2.50), HbA1c (OR 1.345, 95% CI 1.08 to 1.67), age (OR
1.026, 95% CI 1.01 to 1.04), and high ALT (OR 1.02, 95%CI 1.01
to 1.04) were associated with higher chance of NAFLD, and
systolic blood pressure was inversely related to NAFLD (OR
0.97, 95% CI 0.96 to 0.99, Table 3).
Fatty liver grade on US showed a significant association
(P < 0.001) with LB. The AUROC of US for diagnosing NAFLD
was 0.75 (95% CI 0.63 - 0.86, P = 0.001, Figure 1). At the cut-
off of grade I, US yielded a sensitivity of 90.2%, PPV of 73%,
specificity of 22.7%, and NPV of 50% for diagnosing NAFLD.
However, it failed to show any association with NASH at this
cut-off (P = 0.583). At cutoff of grade II fatty liver, US yielded
a sensitivity of 72.5%, PPV of 84.1%, specificity of 68.2%, and
NPV of 51.7% for diagnosis of NAFLD (P = 0.002) and sensi-
tivity of 100%, PPV of 15.9%, specificity of 43.9%, and NPV of
100% for diagnosis of NASH (P = 0.024, Table 4).
3.2. Liver Biopsy
Seventy-three patients underwent LB. Their mean BMI
was 45.9± 5.6 kg/m2 with a mean age of 40.1± 10.9 years
with 72% being female. MetS was present in 68.6%, HTN in
30.1%, and DM in 24.3% of this patient subset. Patients with
NAFL or NASH were significantly older and had higher AST
and ALT levels than those with normal liver. However, no
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Table 2. Clinical Characteristics and Biochemical Values of the 1944 Patients with Morbid Obesitya , b
Variable Grade 0 (N = 451) Grade I (N = 482) Grade II (N = 664) Grade III (N = 347) P Valuec
Age, y 36.0± 11.2 37.7± 10.9 # 39.6± 10.3 $, & 39.5± 10.6 $, & < 0.001
Gender, female, No. (%) 372 (82.5) 432 (89.6) 515 (77.6) 224 (64.6) < 0.001
Weight, kg 118.3± 22.4 114.0± 18.3 # 121.5± 21.1 #, £ 131.6± 22.8 $, £, § < 0.001
Height, cm 163.5± 8.6 161.8± 8.3 # 164.4± 9.2 £ 166.1± 9.9 $, £, ¥ < 0.001
BMI, kg/m2 43.8± 6.9 43.3± 5.7 44.7± 6.0 #, £ 47.4± 6.4 $, £,§ < 0.001
Waist circumference, cm 121.8± 14.4 119.4± 13.8 # 124.9± 13.7 $, £ 132.1± 13.8 $, £, § < 0.001
Systolic blood pressure, mmHg 121.9± 12.4 120.5± 12.1 123.9± 12.7 #, £ 124.9± 12.4 $, £ < 0.001
Diastolic blood pressure, mmHg 77.0± 7.8 76.4± 8.6 79.2± 8.9 $, £ 79.2± 9.3 $, £ < 0.001
Hypertension, No. (%) 428 (94.9) 455 (94.4) 580 (87.3) 301 (86.7) < 0.001
Fasting plasma glucose, mg/dL 94 [86 - 101.2] 95 [87 - 105] 101 [92 - 115] $, £ 104 [94 - 128.7] $, £, ¥ < 0.001
Insulin, mIU/L 15.15 [9.30 - 25] 15.2 [10 - 22.52] 17.75 [12 - 25.17] #, £ 21.1 [14.5 - 29.7] $, £, § < 0.001
Hemoglobin A1c, % 5.30 [5 - 5.60] 5.4 [5.1 - 5.9] # 5.6 [5.2 - 6.2] $, £ 5.7 [5.2 - 6.5] $, £, ¥ < 0.001
HOMA-IR 3.60 [2.18 - 6.05] 3.63 [2.31 - 5.73] 4.64 [3.08 - 7.11] $, £ 5.57 [3.81 - 8.2] $, £, § < 0.001
Insulin resistant, No. (%) 194 ( 66.9) 257 (68.9) 423 (81.0) 226 (85.6) < 0.001
Diabetes mellitus, No. (%) 44 (12.1) 72 (15.9) 175 (27.3) 115 (34) < 0.001
Metabolic syndrome, No. (%) 174 (47.4) 252 (55.3) 462 (71.9) 248 (73.4) < 0.001
Triglyceride, mg/dL 128 [94 - 175] 127 [97.5 - 170] 151 [110 - 203] $, £ 157.5 [123 - 206] $, £, ¥ < 0.001
High-density lipoprotein, mg/dL 48.8± 11.5 48.4± 11.5 47.4± 11.3 46.0± 12.2 #, & 0.008
Low-density lipoprotein, mg/dL 113.2± 30.6 112.1± 32.4 111.8± 34.6 108.4± 34.3 0.271
Alkaline phosphatase, IU/L 188.4± 63.1 190.7± 103.8 186.4± 60.6 189.2± 116.7 0.882
AST, U/L 18 [14 - 25] 18 [15 - 24] 20 [16 - 27] $, £ 23 [17 - 33] $, £, § < 0.001
High AST, No. (%)d 38 (8.4) 52 (10.8) 124 (18.7) 92 (26.5) < 0.001
ALT, U/L 20 [15 - 28] 21 [16 - 30] # 25 [18 - 37] $, £ 28 [20 - 45.25] $, £, ¥ < 0.001
High ALT, No. (%)d 63 (14.0) 103 (21.4) 205 (30.9) 125 (36.0) < 0.001
Total cholesterol, mg/dL 193.0± 40.8 190.4± 41.2 192.8± 43.9 190.3± 41.7 0.670
Serum albumin, g/dL 4.30± 0.34 4.29± 0.35 4.34± 0.37 4.32± 0.41 0.312
Platelet count, 103 /microL 279.3± 64.0 285.8± 65.7 282.2± 65.6 277.3± 70.8 0.305
Liver span, cm 14.7± 2.2 15.1± 2.0 15.8± 2.1 #, & 16.4± 2.3 $, £, ¥ < 0.001
Abbreviations: BMI, body mass index; HOMA-IR, homeostatic model assessment of insulin resistance index; AST, aspartate transaminase; ALT, alanine transaminase.
aValues are presented as mean±SD for normally-distributed variables, median [IQR] for not normally-distributed variables, and n (%) for categorical variables.
b#/$ = <0.05/<0.001 vs. normal; &/£ = <0.05/<0.001 vs. grade I; ¥/§ = <0.05/<0.001 vs. grade II
cNormally-distributed variables were analyzed using t-test and ANOVA, and variables with other distributions were analyzed using Mann-Whitney and Kruskal-Wallis
tests.
dHigh transaminase level was defined as AST levels! 33 U/L or 29 U/L and ALT levels! 43 U/L or 30 U/L in men and women, respectively.
difference was observed regarding all other variables, in-
cluding lipid profile and anthropometrics (Table 5).
Biopsy results demonstrated that nearly 70% of pa-
tients had features of NAFLD: 60.3% had NAFL and 9.6% had
NASH. Median NAS was 2 [0 - 4]. The majority of patients
(82%) had < 33% steatosis, 87% had < 2 foci/200x lobular in-
flammation, and 87% had no or few balloon cells in their
biopsies (Table 6). Among other common biopsy features
were the presence of acidophil bodies (95.9%), microgran-
ulomas (92%), and megamitochondria (97.3%). Fibrosis fea-
tures were detected in 17 (23%) patients: 14 patients (19%)
had F1 and three patients had F2, F3, and F4, each.
3.3. NAFLD Fibrosis Score (NFS) and Fibrosis-4 Index (FIB-4)
NFS was calculated in 1077 patients. Four hundred and
forty-five (41.3%) patients had a low risk of fibrosis, com-
pared to 520 (48.3%) with moderate and 112 (10.4%) with
high risk of advanced fibrosis (Table 6). NFS was signifi-
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Table 3. Univariate and Multivariate Logistic Regression Analysis of Factors Associated with Nonalcoholic Fatty Liver Disease in 1944 Patients with Morbid Obesity
Variable Univariate Multivariate
Odds Ratio 95% CI P Value Odds Ratio 95% CI P Value
Diabetes mellitus 2.460 1.757 - 3.446 < 0.001
Metabolic syndrome 2.246 1.780 - 2.834 < 0.001 1.701 1.157 - 2.500 0.007
Hypertension 1.789 1.363 - 2.347 < 0.001
Insulin resistance 1.772 1.337 - 2.348 < 0.001
HbA1c 1.543 1.336 - 1.781 < 0.001 1.345 1.078 - 1.679 0.009
HOMA-IR 1.040 1.007 - 1.074 0.018
High ASTa 1.033 1.019 - 1.046 < 0.001
Age 1.027 1.017 - 1.038 < 0.001 1.026 1.009 - 1.044 0.003
High ALTa 1.026 1.017 - 1.036 < 0.001 1.020 1.001 - 1.038 0.035
BMI 1.026 1.009 - 1.044 0.003
DBP 1.017 1.004 - 1.029 0.011
WC 1.015 1.006 - 1.023 0.001
FPG 1.013 1.008 - 1.018 < 0.001
Weight 1.007 1.002 - 1.012 0.008
TG 1.004 1.002 - 1.006 < 0.001
SBP 1.007 0.998 - 1.017 0.113 0.978 0.963 - 0.993 0.005
Abbreviations: HOMA-IR, homeostatic model assessment of insulin resistance index; AST, aspartate transaminase; ALT, alanine transaminase; BMI, body mass index; DBP,
diastolic blood pressure; WC, waist circumference; FPG, fasting plasma glucose; TG, triglyceride; SBP, systolic blood pressure.
aHigh transaminase level was defined as AST levels≥ 33 U/L or 29 U/L and ALT levels≥ 43 U/L or 30 U/L in men and women, respectively.
Table 4. Diagnostic Performance of Liver Ultrasound, NFS, and FIB-4 Compared to the Gold Standard Liver Biopsya
Diagnostic Test Cutoff Diagnosis AUROC (Range) P Value Sensitivity, % Specificity, % Positive Predictive
Value, %
Negative Predictive
Value, %
Liver ultrasound
Grade 1 NAFL 0.75 (0.63 - 0.86) 0.001 90.2 22.7 73 50
Grade 2 NAFL - 0.002 72.5 68.2 84.1 51.7
Grade 2 NASH - 0.024 100 43.9 15.9 100
NFS -2.5 Fibrosis 0.59 (0.39 - 0.70) 0.382 90.9 25 32.2 87.5
FIB-4 0.5 Fibrosis 0.72 (0.58 - 0.86) 0.010 93.3 43.1 32.5 95.6
Abbreviations: AUROC, area under the receiver operating characteristic curve; NAFL, non-alcoholic fatty liver; NASH, non-alcoholic steatohepatitis; NFS, NAFLD fibrosis
score; FIB-4, Fibrosis-4 index.
aWe calculated optimized cutoffs for liver ultrasound (for diagnosis of NAFL/NASH according to biopsy) and for NFS and FIB-4 (for diagnosis of fibrosis according to
biopsy)
cantly associated with fibrosis (P = 0.042) and SF (P = 0.013).
However, AUROC failed to show statistical significance for
diagnosis of fibrosis or SF (Table 4, Figure 1). Its sensitivity,
specificity, PPV, and NPV for diagnosing fibrosis were 90.9%,
25%, 32.2%, and 87.5%, respectively (Table 4). NFS was also
associated with NAFLD on US, and higher fatty liver grades
were associated with higher NFS and hence, higher fibrosis
risk (P < 0.001, Table 2).
Fibrosis-4 Index was calculated in 1699 patients. Over-
all, 1636 patients (96.2%) had a score below the cutoff of 1.45,
62 (3.2%) between 1.45 and 3.25, and only one patient higher
than 3.25. FIB-4 showed a significant association with the
presence of fibrosis and SF (P = 0.01 and P < 0.001, respec-
tively). AUROC of FIB-4 for diagnosing fibrosis was 0.72 (95%
CI 0.58 - 0.86, P = 0.01) with a sensitivity of 93.3%, specificity
of 43.1%, PPV of 32.5% and NPV of 95.6% at cutoff of 0.5 (Ta-
ble 4, Figure 1). Moreover, three diagnostic categories of
FIB-4 and NFS showed a significant association (P < 0.001);
however, they had minimal agreement (kappa = 0.022, P =
0.028).
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Figure 1. Area under the receiver operating characteristic curves of A, liver ultrasound for diagnosis of nonalcoholic fatty liver disease; B, NAFLD fibrosis score (NFS) for
diagnosis of fibrosis; and C, Fibrosis-4 Index (FIB-4) for diagnosis of fibrosis.
4. Discussion
This study demonstrated the high prevalence of NAFLD
in our bariatric patients at baseline, in up to 76% of patients
according to US, and in 70% of those undergoing LB. In this
latter group, 10% had NASH and 23% had histologic fea-
tures of fibrosis. This high prevalence is significant when
considered together with the strong association that was
found between the presence of NAFLD, and DM, MetS, and
IR, which themselves are on the rise in our country (22).
A recent meta-analysis estimated the global prevalence
of NAFLD in the general population to be around 25%,
with the highest values observed in the Middle East re-
gion, reaching 31% (23). However, in Iran, a population-
based study of 5023 individuals in 2014 yielded an alarm-
ing prevalence of 43.8%, much higher than such estimate
(10). When DM, dyslipidemia, obesity, and MetS are added
to the clinical picture, the overall prevalence increases
dramatically to 70% and higher (5, 10, 24). In the con-
text of severe obesity, a benchmark study of 1000 mor-
bidly obese patients undergoing bariatric surgery revealed
NAFLD prevalence of 80.2%, consisting of 65.9% with simple
steatosis and 14.3% with NASH (25). Our results closely com-
pared to these findings and confirmed the exceptionally
high prevalence of the disease in morbidly obese patients,
both by US and LB. As the increased risk of liver-specific and
overall mortality associated with the severe form of the dis-
ease, NASH, is well established (26, 27), these findings call
for timely prevention and management of patients to pre-
vent NAFL progression towards NASH and liver fibrosis.
Many studies have investigated various clinical and
para-clinical parameters and their association with NAFLD.
These include patient’s age, WC, BMI, HTN, DM, dyslipi-
demia, and high serum ALT, AST, ALP, gamma glutamyl
transferase (GGT), FPG, and HOMA-IR (9, 11, 28-32). Other
novel markers such as hepatic leptin receptor down-
regulation (33), serum alpha-ketoglutarate levels (34), and
most recently, serum cytokeratin-18 levels (35) have also
been suggested. In line with and complementary to these
findings, the current study showed that older age and
higher ALT and AST levels are associated with higher NAS
on LB. Moreover, HTN, DM, MetS, IR and higher weight, BMI,
WC, diastolic blood pressure, AST, ALT, FPG, HbA1c, TG, and
HOMA-IR levels were risk factors for NAFLD. While these pa-
rameters may be of limited predictive value individually
since they are inconsistently associated with NAFL/NASH
across studies, the cumulative presence of these derange-
ments can provide a more reliable clue to an underlying
NAFLD. As such, DM, MetS, dyslipidemia, and obesity may
be the more appropriate and broader entities to look for
when determining the risk of NAFLD (36). They may thus
warrant further evaluation of patients for NAFLD and re-
lated comorbidities.
Developing alternative, noninvasive methods for diag-
nosing NAFLD has attracted significant interest in recent
years. US has always been a simple, feasible, and accessi-
ble method for liver assessment. However, it has mostly
failed to prove reliable and accurate for NAFLD, especially
at higher levels of steatosis (37) or for distinguishing NAFL
and NASH (38). Its lack of accuracy for fibrosis has also been
another shortcoming (39). US demonstrated a sensitivity
of 90% or 72.5% and specificity of 22% or 68% at the cutoff
of grade I or II fatty liver, respectively, alongside a signifi-
cant association with NAS in the current report. This sub-
optimal performance may be explained by lack of NAFLD-
characteristic findings and interference of abdominal wall
Hepat Mon. 2018; 18(5):e64380. 7
Barzin M et al.
Table 5. Clinical, Biochemical, and Metabolic Indices of Patients Undergoing Biopsy (N=73) According to Their Non-Alcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS)
Groupa , b
Variable Normal NAFL / NASH
NAS = 0 (N = 22) 1≤NAS≤ 4 (N = 44) 5≤NAS≤ 8 (N = 7) P Valueb
Age, y 34.0± 10.0 43.5± 10.2 37.5± 10.5 0.002
Sex, female 18 (81.8) 32 (72.7) 3 (42.9) 0.128
Weight, kg 123.8± 20.5 124.3± 19.6 140.5± 16.4 0.601
Height, cm 164.5± 9.0 165.2± 8.8 170.5± 8.5 0.534
BMI, kg/m2 46.1± 6.4 45.4± 5.2 48.2± 5.9 0.845
Waist circumference, cm 123.9± 14.9 127.9± 11.9 133.5± 12.1 0.155
Systolic blood pressure, mmHg 121.8± 8.2 125.0± 10.2 126.4± 18.4 0.216
Diastolic blood pressure, mmHg 75.9± 7.3 77.2± 7.2 80.0± 10.0 0.370
Hypertension 22 (100) 40 (90.9) 5 (71.4) 0.057
Fasting plasma glucose, mg/dL 97.5 [90.25 - 106] 102 [91 - 121] 98 [98 - 123] 0.289
Insulin, mIU/L 18.72 [8.82 - 24.85] 18 [11.48 - 24.7] 27.33 [23.32 - 43.87] 0.725
Hemoglobin A1c, % 5.5 [5.12 - 6.10] 5.50 [5.15 - 6.10] 5.50 [5.10 - 5.60] 0.259
HOMA-IR 4.92 [3.45 - 6.94] 4.36 [3.22 - 6.23] 8.26 [5.60 - 12.88] 0.517
Insulin resistant 12 (75) 27 (81.8) 6 (100) 0.597
Diabetes mellitus 3 (15) 12 (27.9) 2 (28.6) 0.577
Metabolic syndrome 11 (55) 31 (72) 6 (85.7) 0.265
Triglyceride, mg/dL 147 (101 - 173) 170.2± 83.3 193.5± 86.2 0.367
High-density lipoprotein, mg/dL 46.2± 11.2 47.9± 10.7 43.2± 6.6 0.716
Low-density lipoprotein, mg/dL 104.9± 33.5 109.0± 35.7 105.4± 38.0 0.707
Alkaline phosphatase, IU/L 191.2± 50.4 190.5± 48.6 162.7± 47.8 0.727
AST, U/L 16.5 [14.25 - 20.25] 21 [18 - 26.5] 33 [27 - 36] 0.002
Elevated AST 1 (4.5) 8 (61.5) 4 (57.1) 0.011
ALT, U/L 18.5 [15.5 - 22.75] 27.65 [19.75 - 35.25] 37 [33.5 - 56] < 0.001
Elevated ALT 1 (4.5) 14 (31.8) 5 (71.4) < 0.001
Total cholesterol, mg/dL 185.3± 34.9 187.8± 47.8 186.8± 44.7 0.841
Serum albumin, g/dL 4.4± .3 4.5± 0.4 4.3± 0.2 0.812
Platelet count, 103 /microL 280.1± 57.1 268.6± 66.4 226.8± 68.2 0.333
Liver Ultrasound 0.333
Normal (steatosis grade 0) 5 (50) 5 (50) 0
NAFLD (steatosis grades I - III) 17 (27) 39 (62) 7 (11)
Abbreviations: BMI, body mass index; HOMA-IR, homeostatic model assessment insulin resistance index; AST, aspartate transaminase; ALT, alanine transaminase.
aValues are presented as mean±SD for normally-distributed variables, median [IQR] for not normally-distributed variables, and n (%) for categorical variables.
bFor statistical analysis, comparison was performed between two groups of normal (NAS = 0) vs. NAFLD (NAS≥ 1) to increase statistical power, using parametric or
non-parametric tests where appropriate.
fat in morbidly obese patients with US imaging (40). How-
ever, US demonstrated a fair to good AUROC for diagnosing
NAFLD and thus defends its role as a suitable primary work-
up method. Other noninvasive methods for diagnosis of
NAFLD include fatty liver index (FLI) and United States FLI
(USFLI), which have been used and validated by a number
of studies (36, 41). They take into account the ethnicity of
the patient, which may provide a more individualized ap-
proach and prove to be a generalizable tool. Unfortunately
however, the researchers were unable to use and compare
these tools in this study since GGT data was not available.
For noninvasive diagnosis of fibrosis, both NFS and FIB-
8 Hepat Mon. 2018; 18(5):e64380.
Barzin M et al.
Table 6. Non-Alcoholic Fatty Liver Disease Activity Score (NAS) and Fibrosis Stage in 73 Patients Undergoing Liver Biopsy
Item Extent Score Prevalence, %
NAS
Steatosis, %
Gradea
< 5 0 41.1
5 - 33 1 41.1
> 33 - 66 2 16.4
> 66 3 1.4
Microvesicular steatosis 63
Inflammation
Lobular inflammationa
No foci 0 38.4
< 2 foci/200x 1 49.3
2 - 4 foci/200x 2 12.3
> 4 foci/200x 3 0
Microgranulomas, % 92
Large lipogranulomas, % 78
Portal inflammation, % 63
Liver cell injury
Ballooninga
None 0 43.8
Few balloon cells 1 43.8
Many cells/prominent ballooning 2 12.3
Acidophil bodies 95.9
Pigmented macrophages 74
Megamitochondria 97.3
Other findings
Mallory’s hyaline 94.4
Glycogenated nuclei 60.5
Iron deposition 88.7
Total NAS score
Normal 0 30.1
NAFL 1 - 4 60.3
NASH 5 - 8 9.6
Fibrosis stage
None Normal 76.7
Perisinusoidal or periportal F1 19.2
Perisinusoidal or portal/periportal F2 1.4
Bridging fibrosis F3 1.4
Cirrhosis F4 1.4
Abbreviations: NAS, non-alcoholic fatty liver disease activity score; NAFL, non-alcoholic fatty liver, NASH, non-alcoholic steatohepatitis.
aFeature scores added to calculate NAS.
4 have been endorsed by the American Association for the
Study of Liver Diseases (AASLD) (36). NFS has shown a sen-
sitivity of 66.8% and specificity of 87.5% for detecting SF
(15). In the current study, however, AUROC of NFS failed
to show significance, presumably due to the fact that it
has been validated for detection of advanced fibrosis (F3
- F4), although it has also been used for other definitions
of fibrosis, such as SF (15). However, the relatively small
number of patients undergoing LB with only a few patients
with high-stage fibrosis precluded the researchers from in-
vestigating NFS’s accuracy for detecting advanced fibrosis.
Nevertheless, a positive correlation was observed between
NFS and fibrosis on LB, and although at a lower thresh-
old, yielded acceptable performance. We also found that
fatty liver grade on US was associated with higher NFS. On
the other hand, FIB-4 showed an AUROC of 0.72, as well as
significant association with fibrosis on LB. In line with an
AUROC of 0.73 for diagnosing SF in patients with NAFLD
(15), the current report showed that FIB-4 had similar accu-
racy for detecting fibrosis at a lower threshold. At its sug-
gested thresholds, FIB-4 has shown a sensitivity of 64.8%
and specificity of 72.9% (15). However, for diagnosing fibro-
sis, its optimal threshold was 0.5, corresponding to the sen-
sitivity and specificity of 93% and 43%, respectively. The FIB-
4 may thus be used for diagnosis of fibrosis as well. If con-
sistently confirmed in larger studies, a primary finding of
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steatosis on US combined with a high NFS or FIB-4 in the
context of other high-risk conditions (i.e. MetS, DM and IR)
might be used to detect LB candidates.
Although NFS and FIB-4 showed a significant associa-
tion in this study, their agreement for diagnosing fibrosis
was minimal. Besides from the suboptimal power of our
study to compare their performance for diagnosis of ad-
vanced fibrosis, this might be attributable to their variable
utility in patients with various degrees of fibrosis. Despite
the high prevalence of NAFLD, fibrosis was uncommon in
our morbidly obese patients and seen only in mild stages.
Thus NFS, which takes into account both the BMI and IR,
tended to be higher than FIB-4, which is only based on age,
AST, ALT, and platelets. As a result, NFS overestimated fibro-
sis, let alone SF or advanced fibrosis, while FIB-4 showed
better clinical utility. This provides an interesting perspec-
tive which needs to be further investigated in more com-
prehensive studies. Another factor to take into account is
ethnicity, which was shown to influence the accuracy of
these noninvasive tests that were mostly obtained from
studies in white populations (42); this may in turn under-
mine their generalizability.
Finally, although LB is the gold standard and most ac-
curate method for NAFLD diagnosis, it is not always feasi-
ble or justified in all bariatric patients due to its associated
morbidity and very rare mortality risk. On the other hand,
even when LB is performed, interpretation of its results
would be subject to sampling error and inter-observer vari-
ability. There are also limitations in the use of the NAS sys-
tem and a cut point of five for diagnosing NASH, as demon-
strated in a study by Chalasani et al. (36), in which only
75% of patients with definite histologic diagnosis of NASH
had a NAS ≥ 5; this may lead to overlooking a subset of
NASH patients, who scored lower than 5. Nevertheless, LB
is still the most accurate and reliable method of evaluating
NAFLD and fibrosis (36). In light of the current findings,
the authors believe that careful stratification of patients
at baseline by using universal and non-invasive diagnostic
tools, such as liver enzyme levels, US, NFS, and FIB-4 would
identify patients who might further benefit from LB to con-
firm the diagnosis and guide the treatment.
Despite being among the first reports in this region,
the current study had a number of limitations. Because of
the lack of data on GGT, we were not able to calculate FLI or
USFLI, which otherwise would have provided an interest-
ing comparison alongside liver US and LB results. In addi-
tion, although many methods were incorporated to min-
imize missing data, NFS could be calculated in about 72%
and FIB-4 in 87% of patients with NAFLD, which is far from
ideal. The relatively small number of patients undergoing
LB restricted performing more robust analysis (including
sensitivity analysis) and comparisons across different diag-
nostic tools. Lastly, only one pathologist interpreted LB re-
sults due to our limited resources.
In conclusion, this study demonstrated a high preva-
lence of NAFLD but low prevalence of fibrosis in our
bariatric population. Diabetes mellitus and metabolic syn-
drome remain the strongest predictive factors for the pres-
ence of NAFLD and NASH and the importance of immediate
action for their effective prevention and diagnosis cannot
be overemphasized, given the growing pandemic of obe-
sity in the Iranian population and around the world. This
study further evaluated the clinical utility of US, NFS, and
FIB-4, and demonstrated that while they can have specific
uses in practice, they have questionable accuracies and as-
sociation with biopsy findings and may fall short of replac-
ing LB in certain populations, those with mild stages of fi-
brosis. Future follow-up studies of our patients will further
shed light on other aspects of this condition, including its
treatment and prognosis in the short and long term.
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